Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 6avelumab 4Magnetic Resonance Spectroscopy 2Docetaxel 2Cisplatin 2ALT-803 2yeast-CEA vaccine 1vadimezan 1trebananib 1obinutuzumab 1naptumomab estafenatox 1erdafitinib 1enfortumab vedotin 1bicalutamide 1atezolizumab 1Ultrasonography 1Specimen Handling 1Ramucirumab 1Radiosurgery 1Phantoms, Imaging 1PM 01183 1Omacor 1Nivolumab 1Neoadjuvant Therapy 1Mitomycin 1Lycopene 1Leucovorin 1High-Intensity Focused Ultrasound Ablation 1Gemcitabine 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Transitional Cell × Omacor × Clear all
NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡